These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9043663)

  • 61. Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation.
    Brown MS; Goldstein JL; Paris KJ; Burnier JP; Marsters JC
    Proc Natl Acad Sci U S A; 1992 Sep; 89(17):8313-6. PubMed ID: 1518863
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics.
    Nigam M; Seong CM; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1993 Oct; 268(28):20695-8. PubMed ID: 8407887
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Different amino acid replacements in CAAX-tetrapeptide based peptidomimetic farnesyltransferase inhibitors.
    Schlitzer M; Sattler I; Dahse HM
    Arch Pharm (Weinheim); 1999 Apr; 332(4):124-32. PubMed ID: 10327885
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Farnesylation and proteolysis are sequential, but distinct steps in the CaaX box modification pathway.
    Farh L; Mitchell DA; Deschenes RJ
    Arch Biochem Biophys; 1995 Apr; 318(1):113-21. PubMed ID: 7726551
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferase.
    Ding CZ; Batorsky R; Bhide R; Chao HJ; Cho Y; Chong S; Gullo-Brown J; Guo P; Kim SH; Lee F; Leftheris K; Miller A; Mitt T; Patel M; Penhallow BA; Ricca C; Rose WC; Schmidt R; Slusarchyk WA; Vite G; Yan N; Manne V; Hunt JT
    J Med Chem; 1999 Dec; 42(25):5241-53. PubMed ID: 10602709
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Novel lead structures for antimalarial farnesyltransferase inhibitors.
    Kettler K; Sakowski J; Wiesner J; Ortmann R; Jomaa H; Schlitzer M
    Pharmazie; 2005 May; 60(5):323-7. PubMed ID: 15918578
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibiting the "Undruggable" RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products.
    Silva LR; da Silva-Júnior EF
    Curr Med Chem; 2022; 29(2):189-211. PubMed ID: 33719954
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK; Windle JJ; Von Hoff DD
    J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of farnesyltransferase overexpression on cell growth and transformation.
    Nagase T; Kawata S; Nakajima H; Tamura S; Yamasaki E; Fukui K; Yamamoto K; Miyagawa J; Matsumura I; Matsuda Y; Matsuzawa Y
    Int J Cancer; 1999 Jan; 80(1):126-33. PubMed ID: 9935242
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
    Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
    Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Selective modification of CaaX peptides with ortho-substituted anilinogeranyl lipids by protein farnesyl transferase: competitive substrates and potent inhibitors from a library of farnesyl diphosphate analogues.
    Troutman JM; Subramanian T; Andres DA; Spielmann HP
    Biochemistry; 2007 Oct; 46(40):11310-21. PubMed ID: 17854205
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-mitogen-activated protein kinase pathway.
    Goalstone M; Carel K; Leitner JW; Draznin B
    Endocrinology; 1997 Dec; 138(12):5119-24. PubMed ID: 9389491
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mechanistic insight into impact of phosphorylation on the enzymatic steps of farnesyltransferase.
    Pekel H; Guzel M; Sensoy O
    Protein Sci; 2022 Oct; 31(10):e4414. PubMed ID: 36173156
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release.
    Furfine ES; Leban JJ; Landavazo A; Moomaw JF; Casey PJ
    Biochemistry; 1995 May; 34(20):6857-62. PubMed ID: 7756316
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.
    Gwaltney SL; O'Connor SJ; Nelson LT; Sullivan GM; Imade H; Wang W; Hasvold L; Li Q; Cohen J; Gu WZ; Tahir SK; Bauch J; Marsh K; Ng SC; Frost DJ; Zhang H; Muchmore S; Jakob CG; Stoll V; Hutchins C; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1363-6. PubMed ID: 12657283
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synthesis of Non-natural, Frame-Shifted Isoprenoid Diphosphate Analogues.
    Temple KJ; Wright EN; Fierke CA; Gibbs RA
    Org Lett; 2016 Dec; 18(23):6038-6041. PubMed ID: 27934359
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pseudodipeptide inhibitors of protein farnesyltransferase.
    deSolms SJ; Deana AA; Giuliani EA; Graham SL; Kohl NE; Mosser SD; Oliff AI; Pompliano DL; Rands E; Scholz TH
    J Med Chem; 1995 Sep; 38(20):3967-71. PubMed ID: 7562930
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthesis and evaluation of homofarnesoyl-substituted CAAX-peptidomimetics as farnesyltransferase inhibitors and antiproliferative agents.
    Schlitzer M; Sattler I; Dahse HM
    Bioorg Med Chem; 1999 Sep; 7(9):2037-45. PubMed ID: 10530953
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells.
    Frassanito MA; Cusmai A; Piccoli C; Dammacco F
    Br J Haematol; 2002 Jul; 118(1):157-65. PubMed ID: 12100143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.